Log in to save to my catalogue

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for M...

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for M...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A699472191

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for MPS IIIA: a mixed methods approach

About this item

Full title

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for MPS IIIA: a mixed methods approach

Publisher

BioMed Central Ltd

Journal title

Orphanet Journal of Rare Diseases, 2022, Vol.17 (1)

Language

English

Formats

Publication information

Publisher

BioMed Central Ltd

More information

Scope and Contents

Contents

MPS IIIA is a rare, degenerative pediatric genetic disease characterized by symptoms impacting cognition, mobility and behavior; the mean age of death is around 15 years of age. Currently, there are no approved therapies for MPS IIIA. A two-year, multi-center, prospective, descriptive cohort study was conducted to document the natural history cours...

Alternative Titles

Full title

Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for MPS IIIA: a mixed methods approach

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A699472191

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A699472191

Other Identifiers

ISSN

1750-1172

E-ISSN

1750-1172

DOI

10.1186/s13023-022-02208-w

How to access this item